Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 10 of 10

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Long-term efficacy and safety of pegcetacoplan over 36 months including 12-month results of the GALE open-label extension study

Ashkan Michael Abbey; Charles C Wykoff; Jeffrey S Heier; Chao Li; Felix Yemanyi; Gabriela Dieckmann; Daniel Pereria; Min Tsuboi; Caroline Baumal

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):380.

ARVO Annual Meeting Abstract June 2024

The DAVIO 2 trial: a phase 2, randomized, double-masked, controlled multicenter study of EYP-1901 vs aflibercept in previously treated wet age-related macular degeneration

David Aaron Eichenbaum; Vrinda Hershberger; Sunil S Patel; Ashkan Michael Abbey; W Zachery Bridges; Arshad M. Khanani; Stephanie Ruggiero; Monica Roy; Jay S Duker; Dario A Paggiarino

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4401.

ARVO Annual Meeting Abstract June 2024

Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study

Ohidul Mojumder; Aamir Abdul Aziz; Hannah Khan; Ashkan Michael Abbey; Robert L Avery; Himanshu K Banda; Mark Rami Barakat; Ramanath Bhandari; Emmanuel Chang; Sara Haug; Nikolas London; Veeral Sheth; Jeremy Wolfe; Michael Andrew Singer; Carl J Danzig; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5675.

ARVO Annual Meeting Abstract June 2023

The DAVIO trial: a phase 1, open-label, dose-escalation study of a single injection of EYP-1901 (vorolanib in Durasert ® platform) demonstrating reduced treatment burden in wet age-related macular degeneration

Ashkan Michael Abbey; Sunil S Patel; Mark Barakat; Vrinda S Hershberger; William Z Bridges; David Aaron Eichenbaum; David Lally; Philip P Storey; Monica Roy; Jay S Duker; Dario A Paggiarino

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):931.

ARVO Annual Meeting Abstract June 2023

The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study

Aamir Abdul Aziz; Hannah Khan; Ashkan Michael Abbey; David RP Almeida; Robert L Avery; Himanshu K Banda; Mark Barakat; Ramanath Bhandari; Emmanuel Y Chang; Sara Haug; Nikolas J S London; Veeral Sheth; Jeremy Wolfe; Michael Andrew Singer; Carl J Danzig; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2190.

ARVO Annual Meeting Abstract June 2023

Visual and Anatomic Outcomes in nAMD Patients with Subretinal Hemorrhage After Treatment with Faricimab in the TRUCKEE Study

Hannah Khan; Aamir Abdul Aziz; Ashkan Michael Abbey; David RP Almeida; Robert L Avery; Himanshu K Banda; Mark Barakat; Ramanath Bhandari; Emmanuel Y Chang; Sara Haug; Nikolas J S London; Veeral Sheth; Jeremy Wolfe; Michael Andrew Singer; Carl J Danzig; Arshad M. Khanani

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2187.

ARVO Annual Meeting Abstract June 2020

Refractive Outcomes after Sutureless Intrascleral Fixation of Secondary Intraocular Lens with Pars Plana Vitrectomy

Ramon Lee; Nathan Farley; Ashkan M Abbey; Maxwell S Stem; George A. Williams; Lisa F Faia; Tarek S Hassan; Alan J Ruby; Sandeep Randhawa; Jeremy D Wolfe

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1657.

ARVO Annual Meeting Abstract April 2014

Successful management of ocular juvenile xanthogranuloma using off-label bevacizumab: a report of 2 cases

Noy Ashkenazy; Christopher M Henry; Ashkan M. Abbey; Craig A McKeown; Audina M Berrocal; Timothy G Murray

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5428.

ARVO Annual Meeting Abstract March 2012

Staphylococcus aureus Endophthalmitis: Antibiotic Susceptibilities, Methicillin Resistance, and Clinical Outcomes

Ashkan M. Abbey; Darlene Miller; Harry W. Flynn, Jr.

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1689.

ARVO Annual Meeting Abstract April 2009

Comparative Peripheral Corneal Thickness by Ultrasound Pachymetry, Artemis-2, Orbscan, and Pentacam

A. M. Abbey; R. H. Silverman; C. E. Starr

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):3683.

Advertisement